EUVIMEDEUVIMED entdecken
Open Access

Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses

Grant S Hansman iD, Gargi Kher iD, Anna D Svirina, Jeremy R H Tame, Lauren Hartley-Tassell, Hiro Irie, Thomas Haselhorst, Mark von Itzstein iD, Penny A Rudd, Marie Pancera iD

Journal of Virology · 2024

DOI: 10.1128/jvi.00707-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Grant S Hansman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Glycomics, Griffith University, Gold Coast Campus, Gold Coast, Queensland, Australia. Hauptthemen laut MEDLINE: Norovirus, Single-Domain Antibodies, Capsid Proteins, Caliciviridae Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human norovirus was discovered more than five decades ago and is a widespread cause of outbreaks of acute gastroenteritis. There are no approved vaccines or antivirals currently available. However, norovirus inhibitors, including capsid-specific monoclonal antibodies (Mabs) and nanobodies, have recently shown promising results. Several Mabs and nanobodies were found to inhibit norovirus replication using a human intestinal enteroid (HIE) culture system and/or could block norovirus attachment to histo-blood group antigen (HBGA) co-factors. In our pursuit to develop a single broad-spectrum norovirus therapeutic, we continued our analysis and development of a cross-reactive and HBGA interfering nanobody (NB26). To improve NB26 binding capacity and therapeutic potential, we conjugated NB26 onto a human IgG Fc domain (Fc-NB26). We confirmed that Fc-NB26 cross-reacts with genetically diverse GII genotype capsid protruding (P) domains (GII.8, GII.14, GII.17, GII.24, GII.26, and GII.NA1) using a direct enzyme-linked immunosorbent assay. Furthermore, X-ray crystallography structures of these P domains and structures of other GII genotypes reveal that the NB26 binding site is largely conserved, validating its broad reactivity. We showed that Fc-NB26 has ~100-fold higher affinity toward the norovirus P domain compared to native NB26. We also found that both NB26 and Fc-NB26 neutralize human norovirus replication in the HIE culture system. Furthermore, the mode of inhibition confirmed that like NB26, Fc-NB26 caused norovirus particle disassembly and aggregation. Overall, these new findings demonstrate that structural modifications to nanobodies can improve their therapeutic potential. IMPORTANCE Developing vaccines and antivirals against norovirus remains a challenge, mainly due to the constant genetic and antigenic evolution. Moreover, re-infection with genetically related and/or antigenic variants is not uncommon. We further developed our leading norovirus nanobody (NB26) that indirectly interfered with norovirus binding to HBGAs, by converting NB26 into a dimeric Fc-linked Nanobody (Fc-NB26). We found that Fc-NB26 had improved binding affinity and neutralization capacity compared with native NB26. Using X-ray crystallography, we showed this nanobody engaged highly conserved capsid residues among genetically diverse noroviruses. Development of such broadly reactive potent therapeutic nanobodies delivered as a slow-releasing prophylactic could be of exceptional value for norovirus outbreaks, especially for the prevention or treatment of severe acute gastroenteritis in high-risk groups such as the young, elderly, and immunocompromised.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NorovirusSingle-Domain AntibodiesCapsid ProteinsCaliciviridae InfectionsHumansAntiviral AgentsImmunoglobulin Fc FragmentsAntibodies, ViralCross ReactionsCapsidBlood Group AntigensVirus ReplicationGastroenteritisImmunoglobulin GAntibodies, MonoclonalAntibodies, Neutralizing

Stichwörter der Autor:innen

antiviral agentsnorovirusesstructural biology

Substanzen

Single-Domain AntibodiesCapsid ProteinsAntiviral AgentsImmunoglobulin Fc FragmentsAntibodies, ViralBlood Group AntigensImmunoglobulin GAntibodies, MonoclonalAntibodies, Neutralizing

Autor:innen und Institutionen

  • Institute for Glycomics, Griffith University, Gold Coast Campus, Gold Coast, Queensland, Australia.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Octapharma Biopharmaceuticals GmbH, Heidelberg, Germany.
  • Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan.
  • School of Environment and Science, Griffith University, Gold Coast Campus, Gold Coast, Queensland, Australia.

ORCID-Profile: Grant S Hansman, Gargi Kher, Mark von Itzstein, Marie Pancera

Förderung

  • NCI NIH HHS

Zitieren

APA

Hansman, G. S., Kher, G., Svirina, A. D., Tame, J. R. H., Hartley-Tassell, L., Irie, H., Haselhorst, T., von Itzstein, M., Rudd, P. A., & Pancera, M. (2024). Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses. Journal of Virology. https://doi.org/10.1128/jvi.00707-24

Vancouver

Hansman GS, Kher G, Svirina AD, Tame JRH, Hartley-Tassell L, Irie H, et al. Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses. Journal of Virology. 2024. doi:10.1128/jvi.00707-24

BibTeX
@article{Hansman2024,
  author = {Hansman, Grant S and Kher, Gargi and Svirina, Anna D and Tame, Jeremy R H and Hartley-Tassell, Lauren and Irie, Hiro and Haselhorst, Thomas and von Itzstein, Mark and Rudd, Penny A and Pancera, Marie},
  title = {Development of a broad-spectrum therapeutic Fc-nanobody for human noroviruses},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.00707-24}
}
Kostenlos starten →